Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
2d agoen
From the article
Conditions : Multiple Myeloma (MM) Interventions : Drug: Sonrotoclax; Drug: CM336 (BCMA/CD3 bispecific antibody) Sponsors : Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
https://doi.org/10.1056/NEJMoa2517384
doi.org·1mo ago
Untitled
doi.org·22d ago
GlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancer
GSK·17y ago
GlaxoSmithKline and Genmab seek European marketing authorisation of Arzerra™ (ofatumumab) in advanced stage blood cancer
GSK·17y ago
ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee
pharmaphorum·13h ago
Medical Education Session: Distinguishing ATTR and AL Amyloidosis for Australian Clinicians
This article appears to be an introductory or promotional piece for a medical education session on distinguishing transthyretin (ATTR) amylo
mdsc.pe·14d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.